Celgene's MM-020 shows positive safety benefit for Revlimid, says RBC Capital


RBC Capital said a letter from Spring 2013 from Celgene to EU physicians reports that interim analysis of M -020 showed positive safety benefit for Revlimid on secondary primary malignancies. The firm views the data as positive, and if confirmed, would remove overhang risk that Revlimid causes cancers and is harmful.

View Comments (0)